TraP Hep C group2025-11-202025-11-202022-04-19TraP Hep C group 2022, 'High Rate of Hepatitis C Virus Reinfection Among Recently Injecting Drug Users: Results From the TraP Hep C Program-A Prospective Nationwide, Population-Based Study', Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 75, no. 10, pp. 1732-1739. https://doi.org/10.1093/cid/ciac2721058-483856721899ec874dc5-0e3b-4cd8-95fc-2cbbc709152c35438144unpaywall: 10.1093/cid/ciac27285141934363https://hdl.handle.net/20.500.11815/6739Publisher Copyright: © The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.BACKGROUND: The Treatment as Prevention for Hepatitis C program started in 2016 in Iceland, offering treatment with direct-acting antivirals to hepatitis C virus (HCV)-infected individuals. Reinfections through injection drug use (IDU) can hamper elimination efforts. We determined reinfection rates of HCV among patients in the program. METHODS: Clinical data were gathered prospectively. The study cohort consisted of HCV-cured patients with an estimated sustained virologic response between 1 February 2016 and 20 November 2018, with follow-up until 20 November 2019. The observation period and time until reinfection was estimated using a single random point imputation method coupled with Monte Carlo simulation. The reinfection rates were expressed as reinfections per 100 person-years (PY). RESULTS: In total, 640 treatments of 614 patients (417 male; mean age, 44.3 years) resulted in cure, with 52 reinfections subsequently confirmed in 50 patients (37 male). Follow-up was 672.1 PY, with a median time to reinfection of 232 days. History of IDU was reported by 523 patients (84.8%) and recent IDU with 220 treatments (34.4%). Stimulants were the preferred injected drug in 85.5% of patients with a history of IDU. The reinfection rate was 7.7/100 PY. Using multivariate Cox proportional hazards models for interval-censored data, age (hazard ratio, 0.96 [95% confidence interval, .94-.99]) and recent IDU (2.91 [1.48-5.76]) were significantly associated with reinfection risk. CONCLUSIONS: The reinfection rate is high in a setting of widespread stimulant use, particularly in young people with recent IDU. Regular follow-up is important among high-risk populations to diagnose reinfections early and reduce transmission. CLINICAL TRIALS REGISTRATION: NCT02647879.84889101732-1739eninfo:eu-repo/semantics/openAccessharm reductionhepatitis Cinjection drug usereinfectiontreatment programRecurrenceProspective StudiesHumansSubstance Abuse, Intravenous/complicationsMaleReinfectionDrug UsersIncidenceHepatitis C/drug therapyAntiviral Agents/therapeutic useAdolescentAdultHepatitis C, Chronic/drug therapyHepacivirusMicrobiology (medical)Infectious DiseasesSDG 3 - Good Health and Well-being/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article10.1093/cid/ciac272